Physician profile
Dmitri Sychev
NPI 1881808277
$2,039.99
in general payments reported to CMS, 2019-2025
23 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2021: $58.65 · 2022: $47.49 · 2023: $145 · 2024: $506 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,813 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,812.66 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $277.58 | 2024-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.56 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $225.79 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $189.23 | 2021-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $153.94 | 2021-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $131.99 | 2024-2025 | |
| Novo Nordisk INC | $123.12 | 2024-2025 | Ozempic, Rivfloza |
| Bayer Healthcare Pharmaceuticals INC. | $96.48 | 2023-2025 | |
| Travere Therapeutics, INC. | $90.31 | 2019-2025 | |
| Amgen INC. | $88.77 | 2025 | Krystexxa |
| Ardelyx, INC. | $55.66 | 2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $54.56 | 2021-2024 | Lupkynis |
| Scpharmaceuticals INC. | $49.92 | 2024 | |
| Averitas Pharma INC. | $34.35 | 2025 | Qutenza |
| Alexion Pharmaceuticals, INC. | $31.83 | 2025 | Ultomiris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $29.18 | 2025 | Acthar |
| Vifor Pharma, INC. | $28.12 | 2024 | Veltassa |
| Boston Scientific Corporation | $27.28 | 2025 | Watchman |
| Lilly USA, LLC | $26.24 | 2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $26.02 | 2024 | Oxlumo |
| Genzyme Corporation | $24.42 | 2022 | |
| Ani Pharmaceuticals, INC. | $23.07 | 2022 | |
| Daiichi Sankyo INC. | $15.57 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitri Sychev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.